Table. Baseline Characteristics of the Study Population.
| Characteristic | All (N = 560), No. (%) |
|---|---|
| Age, median (IQR), y | 68 (59 to 74) |
| Sex | |
| Male | 346 (61.8) |
| Female | 214 (38.2) |
| SBP, median (IQR), mm Hg | 115 (105 to 130) |
| Ischemic heart disease | 57 (10.2) |
| Diabetes | 56 (10) |
| Hypertension | 156 (27.9) |
| Atrial fibrillation | 70 (12.5) |
| eGFR, mL/min | 71 (55 to 90) |
| NYHA class | |
| I | 95 (19.4) |
| II | 301 (61.4) |
| III | 79 (16.1) |
| IV | 15 (3.1) |
| NT-proBNP, median (IQR), ng/L | 2148 (518 to 5751) |
| Troponin T, median (IQR), ng/mL | 50 (24 to 106) |
| κ/λ Ratio, median (IQR) | 8 (1.3 to 23.3) |
| VGPR or CR at 1 mo | 167 (29.8) |
| IVS, median (IQR), mm | 14 (11 to 16) |
| RWT, median (IQR) | 0.62 (0.51 to 0.77) |
| E/e′ ratio, median (IQR) | 12.7 (9.2 to 18.2) |
| LVEF, median (IQR), % | 58 (51 to 62) |
| GLS, median (IQR), % | −14.5 (−19.1 to −10.5) |
| ECV, median (IQR), % | 0.45 (0.36 to 0.53) |
| β-Blockers | 134 (23.9) |
| ACEi/ARBs | 169 (30.2) |
| Loop diuretic | 286 (51.1) |
| MRAs | 64 (11.4) |
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CR, complete response; ECV, extracellular volume; E/e′, ratio of E-wave velocity to peak e′ velocity; eGFR, estimated glomerular filtration rate; GLS, global longitudinal strain; IVS, interventricular septum thickness; LVEF, left ventricular ejection fraction; MRAs, mineralocorticoid receptor antagonists; NT-proBNP, N-terminal pro–B-type natriuretic peptide; NYHA, New York Heart Association; RWT, relative wall thickness; SBP, systolic blood pressure; VGPR, very good partial response.